InnoCare Pharma Limited (HKG:9969)
Hong Kong · Delayed Price · Currency is HKD 14.14
-0.51 (-3.48%)
Nov 21, 2025, 11:59 AM HKT
InnoCare Pharma Revenue
InnoCare Pharma had revenue of 383.89M CNY in the quarter ending September 30, 2025, with 38.09% growth. This brings the company's revenue in the last twelve months to 1.43B, up 58.75% year-over-year. In the year 2024, InnoCare Pharma had annual revenue of 1.01B with 36.68% growth.
Revenue (ttm)
1.43B CNY
Revenue Growth
+58.75%
P/S Ratio
17.96
Revenue / Employee
1.31M CNY
Employees
1,089
Market Cap
28.01B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.01B | 270.91M | 36.68% |
| Dec 31, 2023 | 738.54M | 113.13M | 18.09% |
| Dec 31, 2022 | 625.40M | -417.63M | -40.04% |
| Dec 31, 2021 | 1.04B | 1.04B | 76,368.70% |
| Dec 31, 2020 | 1.36M | 117.00K | 9.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 38.89B |
| Sino Biopharmaceutical | 33.49B |
| Alibaba Health Information Technology | 32.81B |
| CSPC Pharmaceutical Group | 28.49B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |